CAPRO™ Platform
Patented polymer excipient · Release by design
MORE™ Platform
Patent-pending oral wafer · OTC + Rx
Long-Acting Injectables
SubQ · IM · IA · Biodegradable implant
Home› Partner With Trekka
For Formulation & Development Teams Two Proprietary Platforms

When standard excipients fail,
CAPRO™ was built for exactly this.

Heads of formulation and development come to Trekka when their molecules hit a ceiling — burst release, biologic instability, poor loading, or a delivery format that limits the indication. CAPRO™ and MORE™ were engineered at the chemistry level to break through each one. GMP-ready. Pre-IND FDA feedback received — regulatory path confirmed.

CAPRO™ + MORE™ — What changes when you partner
WITHOUT CAPRO™ Burst release Toxic zone Day 0 → Day 90 Biologic degradation Acidic byproducts · Solvent damage Organic solvents required NMP · DCM · DMSO ICH Q3C limits · Regulatory burden Duration ceiling Days–weeks only · Narrow window Limited by polymer Mw C CAPRO™ cleavable linker architecture WITH CAPRO™ Zero burst release Therapeutic window Sustained · By design Biologic compatible Neutral pH · Room-temp mixing 100% solvent-free Physical mixing only ICH Q3C compliant by default Days → 12+ months Linker-tunable · Any duration Same blocks · Different linker SubQ · IM · IA · Implant Small mol · Biologic · Combo GMP-compatible process in development Pre-IND FDA ✓ All inquiries confidential · Response within 48 hours · No commitment required
Why formulation teams choose Trekka

Six reasons heads of development bring their molecules to us.

These aren't marketing claims. They are the specific technical and operational capabilities that make CAPRO™ and MORE™ different from every other platform option available today.

01
Release kinetics programmed at the chemistry level
Cleavable linker architecture gives you precise control over release profile — zero-order flat, first-order gradient, or anything between. Duration tunable from days to 12+ months by linker selection alone. No process tricks, no black box.
Zero burst by design
02
Full biologic compatibility — proteins, peptides, nucleic acids
Room-temperature physical mixing, neutral pH degradation products, no organic solvents. Biologics are not denatured during formulation or in vivo. High protein activity retention confirmed after freeze-drying — critical for vaccines and peptide therapeutics.
Biologic-safe · Room temp
03
No organic solvents — zero residual solvent risk
CAPRO™ formulation is entirely solvent-free. Physical mixing at room temperature means no NMP, DCM, or DMSO — eliminating residual solvent limits, reducing regulatory burden, and preserving API integrity throughout the process.
ICH Q3C compliant by default
04
Scalable manufacturing — simple, GMP-compatible process
GMP-compatible manufacturing is being developed alongside pre-clinical programs. Simple physical mixing eliminates the solvent emulsion and microsphere atomization complexity that has kept PLGA depot manufacturing difficult to scale for 35 years.
Simple process · Scalable by design
05
505(b)(2) pathway built into every program
Trekka's regulatory strategy is designed around 505(b)(2) from day one — leveraging existing safety data to significantly reduce development cost and timelines. Pre-IND FDA feedback already received — regulatory path confirmed, reducing early-stage uncertainty for partners.
Pre-IND feedback complete
06
Works for small molecules, biologics, and combinations
Unlike polyester microsphere platforms constrained to small molecules, CAPRO™ handles the full spectrum — small molecules, peptides, proteins, nucleic acids, and combination formulations — across SubQ, IM, intra-articular, and biodegradable implant formats.
Full API spectrum
The technical case is simple: CAPRO™ solves what other platforms can't — at the molecular level, not through process engineering
Burst release, acidic degradation, biologic incompatibility, and limited duration range are structural problems in legacy platforms. They cannot be solved by process optimisation. CAPRO™ addresses each one through polymer architecture — cleavable linkers, neutral byproducts, solvent-free processing — that was designed specifically for the challenges formulation teams face today.
Platform technical specifications

Two platforms. Designed for the molecules that don't fit anywhere else.

CAPRO™ is a patented injectable depot platform for small molecules, biologics, and combination formulations. MORE™ is a patent-pending oral wafer for rapid transmucosal delivery. Both are advancing through pre-clinical, with GMP-compatible manufacturing being developed in parallel.

Injectable depot
CAPRO™
Cleavable linker polymer · Release by molecular design
Zero burst release
Cleavable linkers pre-program sustained release from first tissue contact. No initial concentration spike, no depot depletion on day one.
Tunable duration: days to 12+ months
Same polymer building blocks, different linker chemistry = entirely different release duration. SubQ, IM, intra-articular, and biodegradable implant formats supported.
Non-toxic, neutral degradation products
Biodegrades to non-toxic, endotoxin-free small molecules at neutral pH. No lactic or glycolic acid accumulation. No inflammatory cascade at the injection site.
Completely solvent-free processing
Physical mixing at room temperature. No NMP, DCM, DMSO. Full API integrity preserved. Zero residual solvent risk at ICH Q3C limits.
High drug loading · Small molecules + biologics
Higher API loading than standard polyester platforms — smaller injection volume, smaller gauge needle. Works for peptides, proteins, nucleic acids, and combinations.
Oral wafer
MORE™
Patent-pending dissolving wafer · Transmucosal delivery
No water required · Rapid oral dissolution
Wafer dissolves completely on contact with saliva. No swallowing, no water needed. Ideal for patient populations where tablet compliance is a problem.
Bypass first-pass metabolism
Transmucosal absorption delivers API directly into systemic circulation — higher bioavailability than oral tablet, faster onset, reduced GI adverse effects.
Solubilises BCS II/IV molecules
Hydrophobic polymer matrix solubilises poorly water-soluble drugs within the wafer — delivering BCS II and IV molecules transorally that would fail conventional tablet formulation.
Ambient storage · Cold chain eliminated
MORE™ wafer format is stable at room temperature — confirmed in vivo immune response maintained after 5-day ambient storage. Eliminates cold chain requirements and distribution complexity.
OTC and Rx — no IND required for OTC programs
MORE™ supports both Rx development and OTC product differentiation. OTC wafer programs can move to market significantly faster than any injectable or Rx reformulation program.
Formulation challenges we address

The eight problems formulation teams bring to Trekka.

Every molecule that arrives at Trekka has hit one of these walls. CAPRO™ and MORE™ were designed specifically to address each one at the chemistry level — not work around them.

Burst release & poor PK profile
Day-1 spikes above the therapeutic window, rapid depot depletion, peak-trough variation driving safety and efficacy problems.
CAPRO™ — zero burst by linker design
Biologic instability
Peptides, proteins, and vaccines degrading during formulation, storage, or in vivo — from acidic byproducts, heat, shear, or solvent exposure.
CAPRO™ — neutral pH, solvent-free, room temp
Short half-life & high dosing frequency
Drugs clearing too fast — requiring daily or weekly administration that is clinically inconvenient and drives non-adherence.
CAPRO™ — depot duration days to 12+ months
Residual solvents & excipient toxicity
NMP, DCM, or other process solvents creating residual limits, regulatory scrutiny, and patient safety liability.
CAPRO™ — 100% solvent-free processing
Poor solubility (BCS II/IV)
Hydrophobic molecules that can't dissolve at therapeutic concentrations — limiting oral bioavailability despite adequate dose.
CAPRO™ + MORE™ — hydrophobic matrix solubilisation
Low drug loading
Existing platforms carry only 3–12% API — requiring large injection volumes or impractical doses to reach therapeutic levels.
CAPRO™ — higher loading, smaller volume
Unpredictable batch-to-batch release
Release profiles dependent on polymer Mw, crystallinity, or water uptake — producing significant batch variability that complicates regulatory submissions.
CAPRO™ — linker-determined, reproducible
Wrong delivery format for the indication
A molecule that needs a different route, form factor, or patient experience — tablet compliance, injection frequency, or cold chain requirements limiting market reach.
MORE™ wafer — oral, no water, ambient stable
How we work together

Four engagement models — structured around your molecule and your goals.

Trekka designs each engagement around what the partner needs. Whether you're looking for a full co-development partner, want to license the platform and run your own program, or need a targeted feasibility study before committing — we have a structure that fits.

Model 1
Feasibility & Proof-of-Concept
Test the platform on your molecule before committing
Trekka runs a targeted formulation feasibility study — demonstrating CAPRO™ or MORE™ performance on your specific API before any long-term agreement. Ideal for development teams who need internal data to justify a larger program.
Defined scope: release profile, stability, or loading targets against your API
4–12 week timeline — fast enough for IND planning decisions
Data package you own — suitable for internal review and regulatory planning
Model 2
Custom Development Program
Full formulation development through pre-clinical
Trekka leads formulation development through pre-clinical studies — bringing platform expertise, formulation science, and 505(b)(2) regulatory strategy to your program as a core development partner.
Full formulation development: optimisation, stability, analytical methods
GMP-compatible manufacturing for clinical batches — being developed alongside pre-clinical programs
505(b)(2) regulatory strategy — pre-IND FDA feedback already received
Model 3
Co-Development
Shared development, shared commercial upside
Trekka and the partner jointly develop the reformulated product — sharing costs, timelines, and commercial rights. Designed for partners with strong clinical and commercial capabilities who want Trekka's formulation and regulatory expertise integrated into the core team.
Joint development agreement with defined milestones and IP ownership
Shared development costs and commercial rights
Trekka contributes platform IP, GMP manufacturing, and regulatory strategy
Model 4
Technology Licensing
License the platform, own the program
License CAPRO™ or MORE™ platform IP and run your own development and commercialisation program. Trekka earns upfront licensing fees and royalties. Full partner control of clinical development, regulatory, and commercial strategy.
Upfront licensing fee for platform access and formulation IP
Per-unit royalties on all commercial product sales
Optional technical support package available from Trekka team
How a program starts

From first conversation to formulation-complete.

Trekka's role is formulation — delivering a characterised, A characterised formulation your team can take forward. Every program starts with a confidential molecule review and moves through defined milestones with full data transparency.

1
Molecule review
Submit API details confidentially. Trekka assesses platform fit and provides a preliminary recommendation.
48 hrs
2
Feasibility study
Targeted experiments on your API — release profile, stability, loading. Data package delivered to your team.
4–12 wks
3
Development agreement
Define engagement model, milestones, and IP terms. Program kicks off on agreed scope.
2–4 wks
4
Formulation development
Full formulation optimisation, analytical methods, stability studies, and GMP batch manufacture.
6–18 months
5
Formulation transfer
Characterised formulation, full data package, and manufacturing process handed to your team. What happens next is yours to lead.
Partner-led
Trekka delivers the formulation — your team takes it from there
Whether you license the platform and run your own program, or engage Trekka for custom development, the output is always the same: a characterised, A characterised formulation and complete data package. Clinical development, regulatory filing, and commercialisation remain entirely in your hands.
Have a molecule that needs
a platform that can actually solve it?
Tell us the API, the formulation challenge, and what you need the formulation to do. We'll show you exactly what CAPRO™ or MORE™ can do — and how fast we can move. All inquiries treated confidentially. Response within 48 hours.
Response within 48 hours
All inquiries confidential
No commitment required